Dec 9 2010
Sunridge International (OTC Bulletin Board: SNDZ), announced today that Ameco Medical is preparing to start the short term clinical trials needed for reimbursement approval.
Ameco Medical Equipment L.L.C., Sunridge's exclusive distributor for several Middle Eastern countries, has invited Dr. Leo D. Bores, Sunridge's medical consultant, to attend the start of their clinical trials. Dr. Bores would be traveling to multiple countries in the Middle East to work with key opinion leaders at some of the largest hospitals and clinics in the region. The purpose of the study will be to achieve reimbursement approval for the PNT procedure throughout the area.
Sunridge International's CEO, G. Richard Smith states, "We strive to have a close working relationship with our distributors so that we can assist them when needed in order to obtain success. Once reimbursement is established, the tens of thousands of glaucoma sufferers can avail themselves of this non-invasive treatment."
Glaucoma is the second leading cause of blindness, affecting over 70 million people worldwide. PNT has been proven (through studies completed over the last 10 yrs) to be a safe, effective, non-invasive and cost effective alternative for treatment for glaucoma and ocular hypertension. The 2-minute treatment has been developed, patented, and distributed by Sunridge International, wholly owned subsidiary, Ophthalmic International www.oi-pnt.com.
Childhood adversity linked to elevated health risks, differing by sex and stress